1. Celgene wins FDA approval for drug key to Bristol buyout — FDA approves TAVR valves for low-risk patients — Warning signs always there for the Novartis-AveXis deal — See more on our front page news

    TRY TWO WEEKS OF OUR EMAIL NEWS HEADLINES FOR FREE
    Dismiss Notice
  2. Dealing with a potential legal issue at work?Ask an Employment Attorney -- a chance to discuss employment-related legal issues with a practicing attorney with over 20 years in employment law experience.
    Dismiss Notice

Culture

Discussion in 'Hollister' started by Anonymous, Aug 1, 2014 at 10:41 PM.

  1. Anonymous

    Anonymous Guest

    Can anyone share the good, the bad and the ugly with this company? I'm actually interested in what type of retirement plan this company offers. Thanks in advance for any info you could provide.
     
  2. Anonymous

    Anonymous Guest

    Don't waste your time. Senior leadership's a joke. They don't care about anyone or anything apart from protecting their own retirement. It used to be a company that cared about the patients first...now it's a company that is focused on trying to recapture momentum as they lose system after system to competitors in ostomy. And the wound care division is even more messed up. Guy running it doesn't have a clue- put all his eggs in the basket of a new collagen that isn't that special, and in partnering with a company from France that is a mess to deal with. Reps are still waiting for "new" products in both wound care and ostomy that have been promised for years. The leadership at this place is so slow moving that they still require ties and coats for men in corporate office. If you are looking at this place- don't. The retirement plan is terrible. Almost no company match on 401k. There is a pension sort of plan, but it takes forever to vest and they use it as a method to justify not paying decent money up front.
     
  3. Anonymous

    Anonymous Guest

    Um. To the above commenter-you're a flaming idiot.

    1) ostomy has had a few issues but they're launching new products and remain the leader.

    2) you must not have any knowledge of wound care. JR Locey is a brilliant man, Endoform IS VERY DIFFERENT (ie it was a skin sub that Hollister got classified as code A) and has exceeded yearly sales goals by mid year since launch. Additionally, we are launching more differentiated products this year that will continue to grow this division into a true leader in the industry. This company does nothing quickly and that's honestly a good thing. They're prudent and don't make knee jerk decisions. You sound like an old bitter ostomy rep or an ex employee-of which there aren't many for a reason.

    Take care!
     
  4. Anonymous

    Anonymous Guest

    Ostomy may be the leader, but the well is drying up quickly. Still getting our butts kicked and losing more and more accounts every day. And the Endoform is not so special. Most reps admit as much. Everyone is just hoping the government doesn't realize it should have always been a different type of product and take away the only real advantage we have.
     
  5. Anonymous

    Anonymous Guest

    Gay R brilliant? That's the funniest thing I've heard since he went back to school. Is he still a hands on manager?
     
  6. Anonymous

    Anonymous Guest

    Hands on what is the real question???
     
  7. Anonymous

    Anonymous Guest

    Did JR go back to school or was that a rouse to hide why he had to leave Healthpoint. Locey spins so many stories you never know the truth.